| dc.contributor.author | Gue, Ying | |
| dc.contributor.author | Gorog, Diana | |
| dc.date.accessioned | 2020-07-28T00:06:48Z | |
| dc.date.available | 2020-07-28T00:06:48Z | |
| dc.date.issued | 2020-07-20 | |
| dc.identifier.citation | Gue , Y & Gorog , D 2020 , ' Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19 ' , European Heart Journal . https://doi.org/10.1093/eurheartj/ehaa534 | |
| dc.identifier.issn | 0195-668X | |
| dc.identifier.uri | http://hdl.handle.net/2299/23010 | |
| dc.description | © 2020 Oxford University Press. This is a pre-copyedited, author-produced PDF of an article accepted for publication in European Heart Journal following peer review. The version of record [Ying X Gue, Diana A Gorog, Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19, European Heart Journal, ehaa534] is available online at: https://doi.org/10.1093/eurheartj/ehaa534. | |
| dc.description.abstract | This commentary refers to ‘Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy’, by R.M. Inciardi et al., doi: 10.1093/eurheartj/ehaa583. | en |
| dc.format.extent | 377496 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | European Heart Journal | |
| dc.title | Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19 | en |
| dc.contributor.institution | Department of Clinical and Pharmaceutical Sciences | |
| dc.contributor.institution | Centre for Health Services and Clinical Research | |
| dc.contributor.institution | Basic and Clinical Science Unit | |
| dc.contributor.institution | School of Life and Medical Sciences | |
| dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
| dc.description.status | Peer reviewed | |
| dc.date.embargoedUntil | 2021-07-20 | |
| rioxxterms.versionofrecord | 10.1093/eurheartj/ehaa534 | |
| rioxxterms.type | Other | |
| herts.preservation.rarelyaccessed | true | |
